CollPlant Biotechnologies (NASDAQ:CLGN) Earns Buy Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of CollPlant Biotechnologies (NASDAQ:CLGN) in a research note published on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $14.00 price objective on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of CollPlant Biotechnologies in a research note on Friday, November 29th.

CollPlant Biotechnologies Price Performance

Shares of CLGN opened at $3.60 on Wednesday. The firm has a 50 day simple moving average of $3.83 and a 200-day simple moving average of $4.28. CollPlant Biotechnologies has a 1-year low of $3.24 and a 1-year high of $6.75. The stock has a market cap of $41.22 million, a price-to-earnings ratio of -2.34 and a beta of 0.86.

CollPlant Biotechnologies (NASDAQ:CLGN) last issued its quarterly earnings data on Wednesday, November 27th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). CollPlant Biotechnologies had a negative return on equity of 77.05% and a negative net margin of 2,680.00%. During the same quarter in the previous year, the firm earned ($0.38) EPS. On average, equities analysts expect that CollPlant Biotechnologies will post -1.44 earnings per share for the current fiscal year.

Institutional Trading of CollPlant Biotechnologies

A number of hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN boosted its position in CollPlant Biotechnologies by 110.1% during the fourth quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock worth $30,000 after acquiring an additional 4,405 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in CollPlant Biotechnologies during the fourth quarter worth approximately $38,000. AMH Equity Ltd boosted its position in CollPlant Biotechnologies by 17.4% during the fourth quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock worth $419,000 after acquiring an additional 17,295 shares during the last quarter. Benjamin Edwards Inc. acquired a new position in shares of CollPlant Biotechnologies in the 3rd quarter valued at $112,000. Finally, Villere ST Denis J & Co. LLC boosted its holdings in shares of CollPlant Biotechnologies by 24.4% in the 3rd quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock valued at $2,407,000 after purchasing an additional 95,000 shares during the last quarter. Institutional investors and hedge funds own 21.69% of the company’s stock.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.